What is IMVT stock price today?

IMVT (Immunovant Inc) stock is trading at $24.50 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is IMVT stock going up or down today?

IMVT stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy IMVT stock now?

The decision to buy IMVT depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is IMVT a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for IMVT based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is IMVT stock overvalued or undervalued?

Use our DCF valuation calculator to determine if IMVT is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is IMVT's P/E ratio?

P/E ratio data for IMVT will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is IMVT's market cap?

IMVT (Immunovant Inc) has a market capitalization of $5.22 billion, making it a small-cap stock.

What is IMVT's price to book ratio?

IMVT trades at a price-to-book (P/B) ratio of 5.10, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does IMVT pay dividends?

IMVT does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is IMVT's dividend yield?

IMVT does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is IMVT stock a good long-term investment?

IMVT's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is IMVT's revenue growth rate?

Revenue growth data for IMVT is available on our dashboard with detailed financial statement analysis.

Profitability metrics for IMVT are available on our dashboard with complete income statement analysis.

What are the risks of investing in IMVT?

Key risks for IMVT include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does IMVT compare to its competitors?

Compare IMVT to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize IMVT's performance and positioning.

What is IMVT's stock price target for 2026?

Our AI model provides price targets for IMVT based on fundamental analysis: Bull case $31.85 (+30%), Base case $28.17 (+15%), Bear case $22.05 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about IMVT?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for IMVT. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is IMVT's next earnings report?

IMVT reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

IMVT - Immunovant Inc

NYSE * Health Care * Biotechnology

$24.50

$-1.15 (-4.48%)

About Immunovant Inc

Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren's disease; and batoclimab for myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and thyroid eye disease. The company was founded in 2018 and is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.

IMVT Key Statistics

Market Cap

$5.22B

P/B Ratio

5.10

EPS

$-2.67

Employees

362

How IMVT Compares to Peers

IMVT is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

N/A

of 5

Growth Rank

N/A

of 5

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
IMVT(This stock)	$5.22B	N/A	0%	0.0%	-
AMGNAmgen Inc	$189.22B	24.7	0%	0.2%	vs AMGN
GILDGilead Sciences	$172.51B	20.5	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$110.97B	28.5	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$79.17B	18.0	0%	0.3%	vs REGN
BIIBBiogen Inc	$25.38B	19.7	-0%	0.1%	vs BIIB

Immunovant Inc Company Information

Headquarters: New York; U.S.A
Website: immunovant.com
Sector: Health Care
Industry: Biotechnology

Data Updated: April 14, 2026 at 4:55 PM EDT

Ready to invest in IMVT?

Commission-free trading available. Affiliate links.

IMVT Lician Score

5% confidence

4.0/10

Neutral

IMVT has a Lician Score of 4/10 (Average). Areas of concern: Growth.

value

5.0

growth

2.0

quality

5.0

momentum

5.0

safety

5.0

The Lician Score is a comprehensive 1-10 rating that evaluates IMVTacross five key dimensions: Value (valuation relative to sector),Growth (revenue and earnings trajectory),Quality (profitability and balance sheet strength),Momentum (price trends and analyst sentiment), andSafety (volatility and risk metrics).

IMVT Financial Snowflake

5-axis analysis across key investment dimensions

4.4/10

Neutral

5.0

Value

Valuation vs. sector peers

2.0

Growth

Revenue & earnings trajectory

5.0

Quality

Profitability & moat strength

5.0

Momentum

Price trends & analyst sentiment

5.0

Safety

Financial stability & risk

Upcoming Events for IMVT

Dashboard

Enter a ticker to analyze